Yondelis . Experience with Trabectedin in an Advanced Sarcoma Patient on Peritoneal Dialysis for End-Stage Renal Failure .

Chemotherapy. 2014 Aug .

Experience with Trabectedin in an Advanced Sarcoma Patient on Peritoneal Dialysis for End-Stage Renal Failure.

Moe MM, Fernandez Teruel C, Soto-Matos A.

Author information Oncology Department, Singleton Hospital, Swansea, UK.

Abstract :

Background: We wanted to evaluate the impact of peritoneal dialysis on trabectedin therapy in terms of side effects, response and levels in the blood and dialysate of a patient on peritoneal dialysis for end-stage renal failure caused by previous ifosfamide therapy. This has not yet been reported in the medical literature.

Methods: We measured the levels of trabectedin in the blood and peritoneal dialysate at different time points before and after the administration of a 3rd cycle of trabectedin (1.5 mg/m2 over 24 h). Toxicity from the treatment was recorded and the response status was evaluated on a CT scan after the 3rd and 6th cycles.

Results: Serum creatinine clearance (Cockcroft-Gault formula) was 8.31 ml/min. The patient had a World Health Organization performance status score of '0' and did not suffer any significant side effects except for grade 2 anaemia. There was no difference in the plasma level of trabectedin just before and after a 3-hour session of peritoneal dialysis. The amount of trabectedin in the peritoneal dialysates was undetectable (limit of quantification: 25.9 pg/ml). The patient achieved stable disease after 3 cycles, and progressive disease was observed after 6 cycles on CT scan.

Conclusion: Our patient did not suffer undue side effects from trabectedin, and peritoneal dialysis did not appear to have an impact on the clearance of the drug.

© 2014 S. Karger AG, Basel.